S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

RNAZ TransCode Therapeutics Inc

9.40

0.03 (0.32%)

Pre Market

Last Updated: 06:36:25

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more TransCode Therapeutics Charts.

TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more TransCode Therapeutics Charts.

TransCode Therapeutics Inc News

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
Thursday 6 February 2025 (2 weeks ago) • PR Newswire (US)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Tuesday 4 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 4 February 2025 (2 weeks ago) • Edgar (US Regulatory)

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Tuesday 4 February 2025 (2 weeks ago) • PR Newswire (US)

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Tuesday 14 January 2025 (1 month ago) • PR Newswire (US)

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Tuesday 7 January 2025 (1 month ago) • PR Newswire (US)

Form DEF 14A - Other definitive proxy statements
Monday 30 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 20 December 2024 (2 months ago) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Thursday 19 December 2024 (2 months ago) • Edgar (US Regulatory)

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
Wednesday 18 December 2024 (2 months ago) • PR Newswire (US)

Form EFFECT - Notice of Effectiveness
Tuesday 17 December 2024 (2 months ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Friday 6 December 2024 (3 months ago) • Edgar (US Regulatory)

More TransCode Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions